|Bid||41.90 x 900|
|Ask||45.00 x 1200|
|Day's Range||41.31 - 45.35|
|52 Week Range||29.01 - 75.72|
|Beta (5Y Monthly)||1.00|
|PE Ratio (TTM)||22.62|
|Earnings Date||Feb 19, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||53.75|
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Feb. 20.) Akebia Therapeutics Inc (NASDAQ: AKBA ) Aptose Biosciences ...
Anika (ANIK) delivered earnings and revenue surprises of 4.88% and 7.75%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Total Revenue Increases 10% Year-over-Year for the Fourth QuarterCompletes Acquisitions of Parcus Medical and ArthrosurfaceCompany Expects Total Revenue Growth in the 40% to 44%.
Anika (ANIK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Anika Therapeutics, Inc. (ANIK) today announced that Dr. Cheryl Blanchard, a member of the Company’s Board of Directors since August 2018, has been named interim Chief Executive Officer, effective immediately, while the Board continues its search to identify a new CEO following the recent passing of Joseph Darling. In connection with Dr. Blanchard’s appointment, the previously announced interim Office of the President has been dissolved. “We are pleased that Dr. Blanchard, a seasoned executive who has previously served as a biotech President and CEO, has agreed to step in as our interim CEO as we search for Anika’s next leader,” said Dr. Joseph Bower, Chairman of Anika's Board of Directors.
First paragraph, first sentence should read: Anika Therapeutics, Inc. (NASDAQ: ANIK) today announced that the Company plans to issue its fourth-quarter and full-year 2019 financial results after the close of the market on Thursday, February 20, 2020 and hold its investor conference call on the same day, Thursday, February 20, 2020, at 5:00 p.m. ET to discuss its financial results, business highlights, and outlook.
This article is for investors who would like to improve their understanding of price to earnings ratios (P/E ratios...
Anika Therapeutics, Inc. (ANIK), a global, integrated joint preservation and regenerative therapies company with products leveraging its proprietary hyaluronic acid (HA) technology platform, today announced it has completed its acquisition of Arthrosurface, a leading, privately-held provider of joint surface and preservation solutions for active patients. Under the previously disclosed terms of the agreement, Anika acquired all outstanding shares of Arthrosurface in exchange for an upfront payment of approximately $60 million in cash from the company’s existing balance sheet, subject to customary closing adjustments. Arthrosurface shareholders will be eligible to receive an additional $40 million contingent upon the achievement of certain regulatory and commercial milestones.
Anika Therapeutics, Inc. (ANIK) announced today with great sadness that Joseph Darling, its President and Chief Executive Officer, passed away unexpectedly on January 29, 2020 in Upstate New York. “We are shocked and greatly saddened by the passing of Joe Darling,” said Joseph Bower, Chairman of Anika's Board of Directors. On behalf of the Board of Directors and all Anika employees, as well as the many people he worked with and mentored over the years, we would like to extend our deepest condolences to the Darling family, including his wife, Maureen, and children, Jon and Jordan.
BEDFORD, Mass., Jan. 24, 2020 -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated joint preservation and regenerative therapies company with products leveraging.
Primo Medical Group, a Massachusetts based medical device manufacturer and incubator, is pleased to announce the sale of its spin-off company Arthrosurface, to Anika Therapeutics.
As part of the acquisition, the executive team will join Anika and continue to lead Parcus under Anika’s leadership.
Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated joint preservation and regenerative therapies company with products leveraging its proprietary hyaluronic acid (HA) technology platform, today announced it has signed agreements to acquire Parcus Medical, a leading, privately-held sports medicine company, and Arthrosurface, a leading, privately-held provider of joint surface and preservation solutions for active patients.
One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will...
The FDA grants accelerated nod to Seattle Genetics' (SGEN) Padcev to treat urothelial cancer. It also assigns Breakthrough Therapy tag to tucatinib for advanced/metastatic HER2-positive breast cancer.
Epizyme (EPZM) gets favorable votes from the FDA's ODAC for tazemetostat in patients with metastatic or locally advanced epithelioid sarcoma not eligible for curative surgery.
Mallinckrodt (MNK) initiates phase IV, multi-center, multiple-dose, open-label study to assess the effects of lead drug Acthar Gel as a therapy option in patients with severe keratitis.
Pacira (PCRX) focuses on improving sales of its flagship product Exparel. The drug's label expansion programs also look encouraging. However, sole dependence on the drug is a constant worry.
Horizon Therapeutics' (HZNP) pipeline candidate, teprotumumab, gets favorable vote from DODAC of the FDA for the treatment of Thyroid Eye Disease.
Biogen's (BIIB) gosuranemab fails to meet primary endpoint in a phase II study evaluating gosuranemab (BIIB092) in patients with progressive supranuclear palsy, a degenerative brain disorder.
Blueprint Medicines' (BPMC) NDA for avapritinib to treat PDGFRA Exon 18 mutant gastrointestinal stromal tumors (GIST) and fourth-line GIST is under FDA review. Other pipeline candidates also advance.